Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +13.05%
#3 Meteora Meteora +11.55%
#4 Bitway Bitway +10.13%
#5 Glidr Glidr +9.59%
#6 Unit Pump Unit Pump +8.98%
#7 Pump.fun Pump.fun +8.98%
#8 OPENLOOT OPENLOOT +8.59%
#9 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.72%
#10 eCash eCash +7.02%
Coin of the day
PulseChain PulseChain
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Rang în acțiuni #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Preț acțiune
$0.55
Ultima sincronizare: 2025-02-11
Capitalizare de piață
$28.90M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Marinus Pharmaceuticals, Inc. (MRNS)

Categorie

Healthcare
Raport P/S pentru Marinus Pharmaceuticals, Inc. (MRNS)
Raport P/S la data de August 2026 TTM: 0.98
Conform celor mai recente rapoarte financiare și prețului acțiunilor Marinus Pharmaceuticals, Inc., raportul P/S actual (TTM) este 0.98. La sfârșitul anului 2022, compania avea un P/S de 1.53.
Istoricul raportului P/S pentru Marinus Pharmaceuticals, Inc. din 2012 până în 2026
Raport P/S la sfârșitul fiecărui an
An Raport P/S Schimbă
2026 (TTM) 0.98 -79.24%
2023 4.72 209.16%
2022 1.53 -78.52%
2021 7.10 -85.33%
2020 48.41 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 161.27 0.00%
Raport P/S pentru companii similare sau competitoare
Companie Raport P/S Diferență raport P/S Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 937.53%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 1,050.68%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 933.60%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 201.18%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH